Key clinical point: Topical antimicrobials are commonly used by EB patients and may affect antibiotic resistance.
Major finding: About 70% of 188 EB patients who reported use of topical products used topical antimicrobials.
Study details: The data come from a cross-sectional, observational study of 202 epidermolysis bullosa patients.
Disclosures: The Epidermolysis Bullosa Clinical Characterization and Outcomes Database used in the study is funded by the Epidermolysis Bullosa Research Partnership and the Epidermolysis Bullosa Medical Research Foundation. Lead author Ms. Shayegan had no financial conflicts to disclose. Several coauthors disclosed relationships with multiple companies including Abeona Therapeutics, Castle Creek Pharmaceuticals, Fibrocell Science, ProQR, and Scioderm.
Shayegan L et al. Pediatr Dermatol. 2020. doi: 10.1111/pde.14102.